Pharmafile Logo
Pharmafocus logo
Advanced Search

Helsinn

Showing 5 posts of 5 posts found.

pharma_pill_manufacturing

Helsinn and MEI Pharma join forces to develop leukaemia drug Pracinostat

August 9, 2016
Manufacturing and Production, Research and Development Helsinn, MEI Pharma, Pracinostat, chronic myeloid leukaemia

Swiss pharmaceutical group Helsinn has entered an agreement with MEI Pharma over the licensing, development and commercialisation of Pracinostat (SB939) …

News
Eisai image

FDA approves Eisai’s chemo side-effects drug

October 15, 2014
Research and Development, Sales and Marketing Eisai, FDA, Helsinn, akynzeo, chemotherapy, cinv

Eisai and Helsinn Healthcare’s Akynzeo (netupitant/palonosetron) has received FDA approval for the treatment of chemotherapy-induced nausea and vomiting (CINV). CINV …

News

Helsinn expands high-potency plant with cytotoxics suite

March 8, 2011
Manufacturing and Production APIs, CMOs, GMP, Helsinn, Helsinn Advanced Synthesis, Swiss pharma contract manufacturing, contract manufacturing, high-potency APIs

Helsinn is on track to complete construction of a new manufacturing plant for cytotoxic active pharmaceutical ingredients in Biasca, Switzerland, …

News

Helsinn restructures API units in Switzerland, Ireland

June 23, 2009
Manufacturing and Production Helsinn

Pharmaceutical group Helsinn is planning to expand its manufacturing capabilities with a new round of investment at a production facility …

News

Helsinn chooses Dublin for R&D investment

April 14, 2009
Research and Development Helsinn

Helsinn Birex Pharmaceuticals is to invest 13 million euros in a new pilot-scale R&D facility in Ireland, to help it …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025